Antisense and RNAi Therapeutics Market Size, Share, And Growth Report 2032

Antisense and RNAi Therapeutics Market Size

The global Antisense and RNAi Therapeutics market size was worth around USD 4.69 billion in 2023 and is predicted to grow to around USD 20.00 billion by 2032 with a compound annual growth rate (CAGR) of roughly 17.5% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Antisense and RNAi Therapeutics market on a global and regional level.

Request Free Sample

Antisense and RNAi Therapeutics Market: Overview

Antisense is a technology that involves the synthesis of nucleic acid strands that bind to the mRNA or splicing site on the pre-mRNA and inactivates it efficiently. It is a predominant technology used by many research institutes, and biotech and pharma companies for various applications like diagnostics, research, and therapeutics. RNAi therapeutics have a vast scope in the treatment of neurodegenerative disorders and cancer. In the treatment of serious chronic and rare diseases, antisense and RNAi therapeutics are new innovative therapeutic options.

The study also includes drivers and restraints for the antisense and RNAi therapeutics along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the antisense and RNAi therapeutics market on a global level. The market is driven due to rising cancer cases globally. Besides, technology advancement and collaborations between pharmaceutical and biotech companies are also rising. Early commercialization of pipeline therapeutics is likely to provide a competitive advantage to the market along with multifactorial disease targeting likely to disclose new avenues for antisense and RNAi therapeutic market in the forecast period. But, the threat of failure, high expenditure on research, and hurdles in drug delivery are some of the factors hindering market growth globally.

The report also provides a company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers, and industry experts. Some of the key players in the antisense and RNAi therapeutics market are Alnylam Pharmaceuticals, Isis Pharmaceuticals, Silence Therapeutics, Santaris, Antisense Therapeutics, and miRagen Therapeutics.

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports, and other sources have also been considered to arrive at the indicated market numbers.Request Free Sample

Antisense and RNAi Therapeutics Market: Segmentation

The study provides a decisive view of the antisense and RNAi therapeutics market by segmenting the market based on technology, route of administration, indication, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 204 to 2032.

On the basis of technology, the antisense and RNAi therapeutics market is divided into RNAi and antisense RNA. The RNAi technology is further sub-segmented into miRNA and siRNA. The antisense RNA held the major share of the market in 2023 owing to its potential use in therapeutics. Besides, these molecules are also tested for the prevention of disease onset and to halt disease progression.

Based on route of administration, the market is segmented into intra-dermal, pulmonary, intraperitoneal, intravenous, topical, and other delivery methods. Scientists in this field are developing new delivery systems like nanocarriers, in order to promote in-vivo delivery of oligonucleotides.

Based on indication, the antisense and RNAi therapeutics market is segmented into oncology, cardiovascular diseases, renal diseases, neurodegenerative diseases, respiratory diseases, genetic diseases, infectious diseases, and other disease indications. The oncology segment held the major share of the market in 2023 as a large number of licensing revenue and research grants are associated with cancer-based trials for RNAi and antisense therapeutics.

Antisense and RNAi Therapeutics Market: Report Scope

Antisense and RNAi Therapeutics Market: Regional Analysis

Regional segmentation includes the current and forecast demand for the Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America is likely to remain the leading region due to a large number of government policies and rising clinical trials which support the process of initiation in developing antisense therapeutics in this region.

This report segments the global antisense and RNAi therapeutics market as follows:

Global Antisense and RNAi Therapeutics Market: Technology Segment Analysis

• RNAi

  • miRNA
  • siRNA
• Antisense RNA

Global Antisense and RNAi Therapeutics Market: Route of Administration Segment Analysis

• Pulmonary
• Intravenous
• Intra-dermal
• Intra-peritoneal
• Topical
• Other

Global Antisense and RNAi Therapeutics Market: Indication Segment Analysis

• Oncology
• Cardiovascular Diseases
• Renal Diseases
• Neurodegenerative Diseases
• Respiratory Diseases
• Genetic Diseases
• Infectious Diseases
• Other Disease Indications

Global Antisense and RNAi Therapeutics Market: Region Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa